Today in Contract Research & Services
Contract Research & Services
TWi Biotechnology completes patient enrollment in AC-201 phase II trial
TWi Biotechnology has completed enrolling patients with acute arthritis of primary gout and elevated serum uric acid in AC-201 phase II trial for gout flare prophylaxis (GFP) during urate-lowering therapy (ULT).
Contract Research & Services > Clinical Trials > News
Latest Contract Research & Services News by Sector
Select a sector from the list or browse by sector below:
Clinical Trials
TWi Biotechnology completes patient enrollment in AC-201 phase II trial
TWi Biotechnology has completed enrolling patients with acute arthritis of primary gout and elevated serum uric acid in AC-201 phase II trial for gout flare prophylaxis (GFP) during urate-lowering therapy (ULT).
Contract Research & Services > Clinical Trials > News
Contract Research & Services > Clinical Trials > News
Novartis' Jakavi demonstrates overall survival of myelofibrosis patients
Novartis' investigational drug, Jakavi, has demonstrated improvement in overall survival of myelofibrosis patients with continuation of spleen size reductions compared to conventional therapy.
Contract Research & Services > Clinical Trials > News
Contract Research & Services > Clinical Trials > News
Contract Research
Civitas wins second MJFF grant to advance CVT-301 research
The Michael J. Fox Foundation for Parkinson's Research (MJFF) has announced a second grant to Civitas Therapeutics to advance the research of its lead product CVT-301.
Contract Research & Services > Contract Research > News
Contract Research & Services > Contract Research > News
NGM, AstraZeneca’s MedImmune partner to develop Diabetes and Obesity therapies
US-based drug discovery company NGM Biopharma and AstraZeneca’s Biologics unit MedImmune have agreed to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell (EEC) program to treat type 2 diabetes and obesity.
Contract Research & Services > Contract Research > News
Contract Research & Services > Contract Research > News
Contract Services
T3D Therapeutics wins exclusive global rights to DB959 from DARA BioSciences
T3D Therapeutics has obtained exclusive global rights to develop and commercialize oral, highly selective, dual nuclear receptor agonist DB959 from DARA BioSciences.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News
Eli Lilly exercises rights to type 2 diabetes drug under deal with Transition Therapeutics
Eli Lilly and Company has opted to presume all development and commercialization rights to type 2 diabetes drug candidate, TT-401, under the deal with Transition Therapeutics.
Contract Research & Services > Contract Services > News
Contract Research & Services > Contract Services > News